
    
      Edoxaban was approved by the Ministry of Food and Drug Safety (MFDS) in Korea (date: 25th,
      August 2015) for the reduction in the risk of stroke and systemic embolism in patients with
      NVAF, treatment of deep vein thrombosis (DVT) and pulmonary embolism. Edoxaban was approved
      by the Taiwan Food and Drug Administration (TFDA) in Taiwan (date: 24th, February, 2016) for
      the prevention of stroke and systemic embolism in adult patients with NVAF with one or more
      risk factors, such as congestive heart failure, hypertension, age at least 75 years, diabetes
      mellitus, prior stroke or transient ischemic attack (TIA), or treatment of deep vein
      thrombosis (DVT) and pulmonary embolism (PE), following 5 to 10 days of initial therapy with
      a parenteral anticoagulant.

      Real world evidence data of routine clinical practice use of edoxaban up to two years will be
      collected and evaluated in approximately 2,500 patients, treated by specialized as well as
      non-specialized physicians in hospital centers.
    
  